Switch theme
Sign up to access all valuation multiples
Jupiter Neurosciences Inc is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to most central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
2016
n/a
LTM Revenue $0.4M
LTM EBITDA n/a
$30.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jupiter Neurosciences has a last 12-month revenue of $0.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Jupiter Neurosciences achieved revenue of n/a and an EBITDA of -$4.6M.
Jupiter Neurosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jupiter Neurosciences valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.2M | n/a | n/a | $0.4M | XXX |
| Gross Profit | n/a | n/a | n/a | XXX | XXX |
| Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
| EBITDA | -$4.2M | -$4.6M | n/a | n/a | XXX |
| EBITDA Margin | -1808% | -Infinity% | NaN% | 0% | XXX |
| Net Profit | -$4.2M | -$5.0M | -$4.8M | XXX | XXX |
| Net Margin | -1801% | -Infinity% | -Infinity% | XXX | XXX |
| Net Debt | $0.1M | $1.7M | $2.1M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Jupiter Neurosciences's stock price is $1.
Jupiter Neurosciences has current market cap of $27.7M, and EV of $30.1M.
See Jupiter Neurosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30.1M | $27.7M | XXX | XXX | XXX | XXX | $-0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Jupiter Neurosciences has market cap of $27.7M and EV of $30.1M.
Jupiter Neurosciences's trades at 81.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Jupiter Neurosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Jupiter Neurosciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $30.1M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | -15.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJupiter Neurosciences's NTM/LTM revenue growth is 884%
Jupiter Neurosciences's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Jupiter Neurosciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Jupiter Neurosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Jupiter Neurosciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanoform | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jupiter Neurosciences acquired XXX companies to date.
Last acquisition by Jupiter Neurosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Jupiter Neurosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Jupiter Neurosciences founded? | Jupiter Neurosciences was founded in 2016. |
| Where is Jupiter Neurosciences headquartered? | Jupiter Neurosciences is headquartered in United States of America. |
| Who is the CEO of Jupiter Neurosciences? | Jupiter Neurosciences's CEO is Mr. Christer Rosen. |
| Is Jupiter Neurosciences publicy listed? | Yes, Jupiter Neurosciences is a public company listed on NAS. |
| What is the stock symbol of Jupiter Neurosciences? | Jupiter Neurosciences trades under JUNS ticker. |
| When did Jupiter Neurosciences go public? | Jupiter Neurosciences went public in 2024. |
| Who are competitors of Jupiter Neurosciences? | Similar companies to Jupiter Neurosciences include e.g. LTR Pharma, Starpharma, Schott Pharma, Nanoform. |
| What is the current market cap of Jupiter Neurosciences? | Jupiter Neurosciences's current market cap is $27.7M |
| What is the current revenue of Jupiter Neurosciences? | Jupiter Neurosciences's last 12-month revenue is $0.4M. |
| What is the current EV/Revenue multiple of Jupiter Neurosciences? | Current revenue multiple of Jupiter Neurosciences is 81.5x. |
| Is Jupiter Neurosciences profitable? | Yes, Jupiter Neurosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
